1Fried MW,Shiffman ML,Reddy KR,et al.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med,2002,347:975-982.
2Hadziyannis SJ,Sette H Jr,Morgan TR,et al.Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration and ribavirin dose.Ann Intern Med,2004,140:346-355.
3Lonardo A,Adinolfi LE,Loria P,et al.Steatosis and hepatitis C virus:mechanisms and significance for hepatic and extrahepatic disease.Mod Pathol,2004,126:586-597.
4Brunt EM,Ramrakhiani S,Cordes BG,et al.Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease.Mod Pathol,2003,16:49-56.
5Ong JP,Younossi ZM,Speer C,et al.Chronic hepatitis C and superimposed nonalcoholic fatty liver disease.Liver,2001,21:266-271.
6Chitturi S,Abeygunasekera S,Farrell GC,et al.NASH and insulin resistance:Insulin hypersecretion and specific association with the insulin resistance syndrome.Hepatology,2002,35:373-379.
7Adinolfi LE,Gambardella M,Andreana A,et al.Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.Hepatology,2001,33:1358-1364.
8Rubbia-Brandt L,Quadri R,Abid K,et al.Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.J Hepatol,2000,33:106-115.
9Kumar D,Farrell GC,Fung C,et al.Hepatitis C virus genotype 3 is cytopathic to hepatocytes:Reversal of hepatic steatosis after sustained therapeutic response.Hepatology,2002,36:1266-1272.
10Perlemuter G,Sabile A,Letteron P,et al.Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion:a model of viral-related steatosis.FASEB,2002,16:185-194.
4Pekow JR, Bhan AK, Zheng H, et al. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer, 2007, 109: 2490-2496.
5Lok AS, Everhart JE, Chung RT, et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.Clin Gastroenterol Hepatol, 2007, 5: 245-254.
6Kumar D, Farrell GC, Kench J, et al. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol, 2005, 20: 1395-1400.
7Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology, 2005, 41: 82-87.
8Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol, 2004, 40: 823-830.
9Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol, 2004, 74: 406-413.
10Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology, 2004, 127(5 Suppl 1): $62- 71.
